These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32661269)

  • 41. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism.
    Ishikawa T; Morimoto S; Ichihara A
    Hypertens Res; 2022 Mar; 45(3):496-506. PubMed ID: 34961793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
    Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
    Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of esaxerenone-a nonsteroidal mineralocorticoid receptor blocker-on nocturnal hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2022 Feb; 45(2):376-377. PubMed ID: 34837032
    [No Abstract]   [Full Text] [Related]  

  • 45. An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension.
    Pitt B; Jaisser F; Bakris G
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1017-1023. PubMed ID: 34595995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
    Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
    Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers.
    Yoshihara K; Fukae M; Kastrissios H; Wada R; Shimizu T; Ishizuka H
    Drug Metab Pharmacokinet; 2023 Oct; 52():100516. PubMed ID: 37690271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
    Kolkhof P; Joseph A; Kintscher U
    Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
    Kolkhof P; Bärfacker L
    J Endocrinol; 2017 Jul; 234(1):T125-T140. PubMed ID: 28634268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized, Double-Blind, Single-Dose, Placebo-Controlled Crossover Study to Evaluate the Effects of Esaxerenone on QTc Interval in Healthy Subjects.
    Mendell J; Kobayashi F; Shimizu T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):709-718. PubMed ID: 32255542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
    Ichikawa S; Tsutsumi J; Sugimoto K; Yamakawa S
    Adv Ther; 2022 Oct; 39(10):4779-4791. PubMed ID: 35976603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
    Bakris G; Yang YF; Pitt B
    Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.
    Liu W; Yu S
    Kidney Dis (Basel); 2023 Jan; 9(1):12-25. PubMed ID: 36756081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of esaxerenone, a nonsteroidal mineralocorticoid receptor blocker, independent of urinary sodium/potassium ratio and salt intake.
    Morimoto S; Ichihara A
    Hypertens Res; 2024 Apr; 47(4):970-971. PubMed ID: 38273001
    [No Abstract]   [Full Text] [Related]  

  • 59. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.
    Capelli I; Gasperoni L; Ruggeri M; Donati G; Baraldi O; Sorrenti G; Caletti MT; Aiello V; Cianciolo G; La Manna G
    J Nephrol; 2020 Feb; 33(1):37-48. PubMed ID: 30989614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
    Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.